FIRSTCIN Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Cefozopran hydrochloride, a third-generation parenteral cephalosporin, was
launched in Japan for the treatment of severe infections in
immunocompromised patients caused by staphylococci and enterococci. Cefozopran
displays a vety broad antibacterial spectrum against Gram-positive and Gram-negative
organisms. It is potently active against Staphylococcus aureus, Enterococcus
faecalis, Pseudomonas aeruginosa and Citrobacter freundii, some of which are
resistant to most other cephalosporins. The superior wide spectrum antibacterial
activity is attributed to its high affinities for penicillin-binding proteins in various
organisms. Cefozopran is resistant to hydrolysis by most chromosomal and plasmidmediated
β-lactamases. Cefozopran is reportedly effective in treating patients with
respiratory tract, urinary tract, obstetrical, gynecological, soft tissue, and surgical infections.
Originator
Takeda (Japan)
Trademarks
Fristcin
FIRSTCIN Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
